Navigation Links
Asthmatx Presents Impact of Bronchial Thermoplasty on Allergy Practices at ACAAI Annual Meeting
Date:11/9/2009

SUNNYVALE, Calif., Nov. 9 /PRNewswire/ -- Asthmatx, Inc. presented the results of a series of studies investigating the effectiveness and safety of bronchial thermoplasty delivered by the Alair® System, and how this new procedure will impact allergy practices, this past weekend in a poster at the 2009 Annual Meeting of the American College of Allergy, Asthma and Immunology (ACAAI), in Miami Beach, Fla.

The poster, titled "Where Could Bronchial Thermoplasty (BT) Fit Into Your Allergy Practice? Lessons Learned from Multiple Bronchial Thermoplasty Clinical Trials," highlighted the clinical results from three randomized clinical trials, which investigated bronchial thermoplasty's effectiveness as a treatment option for patients with severe asthma.

Bronchial thermoplasty is a non-drug procedure developed to treat adults with severe asthma and is designed to provide improved asthma quality of life and control that lasts for at least one year. Bronchial thermoplasty delivered by the Alair System uses thermal energy to reduce the amount of smooth muscle in the lungs, which is associated with airway constriction in asthma patients.

"We have now shown in numerous clinical trials that patients whose severe asthma is uncontrolled by standard medications can now experience clinically significant improvements in their asthma control and their quality of life following treatment with the Alair System," said Glen French, CEO of Asthmatx. "This poster demonstrates that allergists may soon have a new option to consider for their patients with severe asthma."

The poster noted that, while the risks of bronchial thermoplasty include transient worsening of asthma, patients on high doses of inhaled corticosteroids and long-acting bronchodilators with impaired quality of life experience meaningful improvements in their overall asthma status. The poster authors concluded that allergists should consider referring appropriate patients for bronchial thermoplasty when standard medications are not sufficient to control their severe asthma.

In the period immediately following bronchial thermoplasty, there is an expected transient increase in the frequency and worsening of respiratory-related symptoms, which are of the type expected following bronchoscopy in patients with asthma. These events typically occur within a day of the procedure and resolve on average within seven days with standard care. In the long term, fewer bronchial thermoplasty treated patients reported respiratory adverse events and there was a significant decrease in patients reporting asthma (multiple symptoms) adverse events in the Alair-treated group compared to the sham control group.

About Bronchial Thermoplasty Delivered by the Alair System

Bronchial thermoplasty is a non-drug procedure for asthma. The treatment is performed through the working channel of a standard flexible bronchoscope that is introduced through a patient's nose or mouth and into their lungs. The tip of the small diameter Alair catheter is expanded to contact the walls of targeted airways. Controlled thermal energy is then delivered to the airway walls to reduce the presence of airway smooth muscle that narrows the airways in patients with asthma. The minimally invasive procedure, like many other flexible endoscopy procedures, is done under light anesthesia, and the patient returns home the same day.

In October 2009, the Anesthesiology and Respiratory Therapy Devices Panel of the Medical Devices Advisory Committee to the U.S. Food and Drug Administration (FDA) voted to recommend that the Alair® System, a device utilized in bronchial thermoplasty for the treatment of severe persistent asthma in patients 18 years and older, be found approvable with conditions.

CAUTION: The Alair System is an Investigational Device. It is limited by United States law to investigational use. To be used by Qualified Investigators only.

About Asthmatx

Asthmatx is developing catheter-based medical devices for the treatment of asthma. Asthmatx has developed the Alair System to perform an investigational outpatient procedure called bronchial thermoplasty. The Alair System has received a CE Mark for use in the European Union. For more information on Asthmatx visit www.asthmatx.com.

Alair, Asthmatx and the Asthmatx logo are registered trademarks of Asthmatx, Inc.

SOURCE Asthmatx, Inc.


'/>"/>
SOURCE Asthmatx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Asthmatx Receives FDA Advisory Panel Recommendation for Approvable with Conditions for Bronchial Thermoplasty with the Alair(R) System for Severe Asthma
2. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
3. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
4. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
5. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
6. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
7. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
8. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
9. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
10. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
11. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... DUBLIN , May 4, 2016 /PRNewswire/ ... the addition of the  "Global Acute Ischemic ... 2016"  report to their offering.  ... Global Acute Ischemic Stroke Market ... insights into Acute Ischemic Stroke pipeline products, ...
(Date:5/3/2016)... 3, 2016 BioNovus Innovations LLC and ... Advancing Medical Innovation (IAMI) today announced a new ... and medical devices. An agreement between ... to license, develop and commercialize medical innovations advanced ... "This partnership represents a significant advance in our ...
(Date:5/3/2016)... May 3, 2016   BIOTRONIK , a ... announced Food and Drug Administration (FDA) approval of ... provides heart failure patients with access to diagnostic ... have remote monitoring with daily automatic transmission and ... rate in response to physiological demands. ...
Breaking Medicine Technology:
(Date:5/5/2016)... (PRWEB) , ... May 05, 2016 , ... ... Behavioral Health Population Management Platform, announced today that Enlightened Solutions has joined the ... ability to optimize the care continuum for their patients being treated for substance ...
(Date:5/5/2016)... ... ... Liposuction specialist Marcia V. Byrd, MD spoke last month at the Fat ... Louis Airport Hotel. This year’s conference was titled “Living with Lipedema and Dealing with ... in treating Lipedema. Dr. Byrd is considered one of the leading physicians in the ...
(Date:5/5/2016)... ... 2016 , ... Nepenthe Laboratory Services (NLS), a premier drug monitoring and toxicology ... food item donations for Food for Lane County, and to help support awareness for ... of the assembly was to create an exciting atmosphere for the kids at Riverbend ...
(Date:5/5/2016)... Augusta, Kansas (PRWEB) , ... May 05, 2016 , ... ... management for its school nurses. This partnership will enable school health offices to streamline ... located in Butler County, Kansas, just east of Wichita. Augusta public schools serve 2,300 ...
(Date:5/5/2016)... ... May 05, 2016 , ... In an effort to ... a public health promotion and research organization, declared May as “National Sunshine Month.” ... other shifts in cultural behavior over the past several decades, Americans spend more ...
Breaking Medicine News(10 mins):